Estrella Immunopharma, Inc.
ESLA
$1.15
$0.021.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 51.72% | -9.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 273.79% | -87.23% | |||
| Operating Income | -273.79% | 87.23% | |||
| Income Before Tax | -273.79% | 87.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -273.79% | 87.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -273.79% | 87.23% | |||
| EBIT | -273.79% | 87.23% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -235.80% | 87.48% | |||
| Normalized Basic EPS | -236.63% | 87.52% | |||
| EPS Diluted | -235.80% | 87.48% | |||
| Normalized Diluted EPS | -236.63% | 87.52% | |||
| Average Basic Shares Outstanding | 11.36% | 1.96% | |||
| Average Diluted Shares Outstanding | 11.36% | 1.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||